How Fecal Transplants Restore the Metabolic Environment That Makes Immunotherapy Work

April 3, 2026 ·

Thaena Inc.

New research reveals that fecal microbiota transplantation (FMT) doesn't work by transplanting good bacteria—it works by removing the species that block your immune system from responding to cancer immunotherapy. Here's what the science shows, and what it means for patients and clinicians.

Lit Review Friday · Learn Something with Thaena · Published 2026 · Reading time: ~12 minutes

The Results That Changed Everything

In January 2026, researchers published results from the FMT-LUMINate trial—a phase 2 clinical study that combined fecal microbiota transplantation with immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC) and melanoma.¹

The results were striking.

But the most important finding wasn't the response rates. It was why FMT worked—and it completely upended what researchers thought they knew about how to manipulate the microbiome.

The Paradigm Shift: It's Not About Engraftment

For years, the assumption was straightforward: fecal transplants work by transferring beneficial bacteria from a healthy donor to a sick recipient. The "good bugs" colonize the recipient's gut, and their beneficial effects follow.

But when the FMT-LUMINate researchers analyzed the microbiomes of responders versus non-responders, they discovered something unexpected.

Here's the critical insight: this wasn't simply about "removing bad bacteria and adding good ones." It was about restoring a metabolic environment capable of producing the co-stimulatory molecules that prime the immune system for immunotherapy response.

Think of it this way: the species that disappeared after FMT may have been creating conditions—through substrate competition, local pH changes, oxygen consumption, or production of inhibitory metabolites—that prevented beneficial metabolite production. Once the ecosystem shifted, the remaining and enriched bacteria could finally produce the molecules that matter: butyrate, propionate, inosine, tryptophan derivatives, secondary bile acids, and formate.

The authors framed this as "elimination of deleterious taxa," but the mechanistic story is almost certainly more complex. What likely happened is that FMT reset the redox and metabolic balance of the gut ecosystem, allowing it to function as a proper metabolic factory again—one capable of churning out the immune-enhancing compounds that studies like Mager (inosine), Shi (butyrate), and Phelps (formate) have shown directly improve immunotherapy outcomes.

The Mouse Experiment That Proved It

To confirm this finding, researchers designed an elegant experiment. They took post-FMT stool samples from two patients who had responded to immunotherapy and used them to colonize antibiotic-treated, tumor-bearing mice. As expected, these mice showed enhanced anti-tumor immunity when treated with checkpoint inhibitors.

Then came the critical test: they reintroduced the specific bacterial species that had been depleted after FMT in responders—the Enterocloster and Clostridium strains that had disappeared.

The result? The anti-tumor effect was completely abrogated. Adding back these species killed the therapeutic benefit, even in the presence of immunotherapy.

What does this tell us? Not simply that these bacteria are "bad"—but that their presence disrupts the metabolic environment needed for immunotherapy to work. When Enterocloster and Clostridium species dominate, they may outcompete beneficial bacteria for key substrates, alter local redox conditions, shift bile acid ratios, or produce metabolites that suppress immune function. Remove them, and the ecosystem can finally produce the butyrate, inosine, and tryptophan metabolites that activate anti-tumor immunity. Reintroduce them, and that metabolic capacity collapses.

This wasn't correlation. This was mechanistic proof that restoring the right metabolic environment—not just eliminating specific taxa—is required for FMT-mediated therapeutic benefit.

How We Got Here: The Seven-Year Journey to Understanding

The FMT-LUMINate findings didn't emerge in a vacuum. They represent the culmination of nearly a decade of research connecting the gut microbiome to cancer immunotherapy outcomes. Here's the story of how we learned that your gut bacteria might determine whether checkpoint inhibitors save your life.

2018: The Foundation—Antibiotics and Diversity Matter

Two landmark studies published simultaneously in Science established the connection between the gut microbiome and immunotherapy response.

Routy and colleagues discovered that patients who took antibiotics before or during immunotherapy had significantly worse outcomes. When they looked deeper, they found that a specific bacterium—Akkermansia muciniphila—was associated with favorable responses to PD-1 blockade. In mice, they could restore immunotherapy efficacy by giving Akkermansia supplementation.²

Gopalakrishnan and colleagues found that melanoma patients who responded to anti-PD-1 therapy had higher gut microbiome diversity and greater abundance of bacteria in the Ruminococcaceae family (now called Oscillospiraceae). This correlated with enhanced systemic and anti-tumor immunity.³

The message was clear: your gut bacteria influence whether immunotherapy works. But how could clinicians intervene?

2020–2021: The Metabolite Clues and FMT Pilots

In 2020, Mager and colleagues identified a specific mechanism: the metabolite inosine, produced by Bifidobacterium pseudolongum, could directly enhance response to checkpoint inhibitor therapy. Inosine activated A2A receptors on T cells, strengthening their anti-tumor capacity.⁴

This suggested that what bacteria do—the metabolites they produce—might matter more than which bacteria are present.

Then came two pioneering clinical trials testing whether fecal transplants could rescue patients who weren't responding to immunotherapy:

• Baruch and colleagues (2021) gave FMT from immunotherapy responders to 10 patients with refractory melanoma. Three patients responded—and remarkably, all three had received stool from the same "super donor." The FMT altered recipients' gut microbiota to resemble the responding donor and increased immune cell infiltration into tumors.⁵
• Davar and colleagues (2021) conducted a similar trial, combining FMT with anti-PD-1 re-induction in refractory melanoma patients. They observed clinical benefit in a subset of patients and confirmed that FMT successfully reprogrammed the tumor microenvironment.⁶

The proof-of-concept was established: FMT could overcome resistance to immunotherapy. But these were small, last-resort studies in patients who had already failed treatment. The big question remained: Would FMT work in the first-line setting, before resistance developed?

2025: The Mechanism Revealed

Three major studies in 2025 converged to reveal the underlying mechanisms:

• Hadi and colleagues published final survival results from the MIMic phase 1 trial, which tested oral FMT from healthy donors combined with anti-PD-1 in advanced melanoma as first-line therapy. Median overall survival reached 52.9 months—far exceeding historical benchmarks—and long-term survivors showed distinct taxonomic and functional microbiome profiles.⁷
• Shi and colleagues demonstrated that Faecalibacterium prausnitzii and its metabolite butyrate significantly enhance anti-PD-L1 therapy efficacy in natural killer/T-cell lymphoma by downregulating the JAK-STAT pathway and boosting CD8+ T cell activity.⁸
• Phelps and colleagues revealed that exercise improves immunotherapy outcomes by altering gut microbial metabolism. Specifically, exercise stimulates bacteria to produce formate via one-carbon metabolism, and this formate enhances CD8+ T cell anti-tumor immunity through the Nrf2 signaling pathway.⁹

The pattern was undeniable: specific metabolites produced by gut bacteria—inosine, butyrate, formate—directly enhance the immune system's ability to fight cancer and respond to immunotherapy.

The Metabolic Environment Hypothesis

This brings us to the most important insight from the FMT-LUMINate trial—one that synthesizes all the prior research into a coherent framework.

The Cross-Trial Validation

Critically, the Duttagupta team found this same elimination pattern when they reanalyzed data from three previously published FMT oncology trials: Baruch 2021, Davar 2021, and Hadi 2025. In all three studies, clinical responders showed greater loss of deleterious bacterial species compared to non-responders.¹

This isn't a one-off finding. It's a reproducible biological principle.

The Missing Piece: Direct Metabolite Measurement

There's one glaring gap in the FMT-LUMINate study: the researchers didn't measure metabolites directly.

They identified which bacterial species were eliminated and which were enriched. They proved that elimination matters more than engraftment. But they didn't measure the actual molecules—the butyrate, inosine, tryptophan derivatives, bile acids, and formate—that we know from other studies are the functional mediators of microbiome-immune crosstalk.

This is a missed opportunity. We're inferring the metabolic shift based on which bacteria are present, but we don't have direct biochemical proof from the FMT-LUMINate cohort.

That said, the pattern is clear enough to make strong predictions:

While the Duttagupta study didn't measure these directly, the enrichment of bacteria known to produce them—combined with the elimination of species that likely block their production—strongly suggests this is the mechanism at play.

What This Means for Patients and Clinicians

The Accessibility Problem

FMT is not widely available for cancer patients. The trials discussed here used carefully screened healthy donors, specialized preparation protocols, and close medical supervision. This isn't something patients can access at their local oncology clinic—at least not yet.

But the metabolic environment hypothesis opens a different door: if the therapeutic benefit comes from creating conditions for beneficial metabolite production, can we approximate those conditions through other interventions?

Antibiotics: The Silent Saboteur

The clearest, most actionable finding from this research is the devastating effect of antibiotics on immunotherapy outcomes.

Modifiable Factors: What Patients Can Do Now

While we await more accessible FMT protocols, several evidence-based interventions can support the gut ecosystem:

• Dietary fiber and fermented foods. Fiber feeds beneficial bacteria like Faecalibacterium prausnitzii and Oscillospiraceae, enabling them to produce butyrate and other short-chain fatty acids. Fermented foods (yogurt, kimchi, kefir, sauerkraut) deliver both beneficial bacteria and pre-formed metabolites.
• Exercise. The Phelps 2025 study demonstrated that regular endurance exercise reprograms gut bacteria to produce formate, which directly enhances anti-tumor T cell activity. This isn't a vague "lifestyle recommendation"—it's a mechanistic intervention with measurable immunological effects.⁹
• Polyphenol-rich foods. Many beneficial gut bacteria metabolize dietary polyphenols (found in berries, green tea, dark chocolate, nuts) into bioactive compounds that support immune function and reduce inflammation.
• Postbiotics. Postbiotics deliver the finished metabolic products—butyrate, short-chain fatty acids, tryptophan derivatives, bile acids—that FMT studies suggest are key to immunotherapy response. While FMT creates the conditions for these molecules to be produced in situ, postbiotics provide them directly.

The Future: Where This Research Is Headed

Key Questions Still Unanswered

• Can we identify "super donors" prospectively? The Baruch study found that all three responders received FMT from the same donor. What makes a super donor super? Is it their bacterial composition, metabolite production capacity, or something else entirely?
• Can we develop targeted postbiotic consortia? Instead of whole stool transplants, could we engineer specific combinations of beneficial postbiotics—or even deliver the complete stool metabolite mixture—to achieve the same effect more safely and predictably?
• What's the optimal timing? Should FMT (or microbiome-targeted interventions) be given before immunotherapy starts, during treatment, or both? The FMT-LUMINate trial gave a single FMT dose before ICI initiation—would repeated dosing improve outcomes further?
• Which patients benefit most? Are there baseline microbiome signatures that predict who will respond to FMT? Can we stratify patients based on their gut ecosystem and tailor interventions accordingly?

The Bigger Picture: Pharmacomicrobiomics

The immunotherapy-microbiome story is part of a larger revolution in medicine: the recognition that gut bacteria fundamentally alter how drugs work in the human body.

Just as we've learned that bacteria can activate anti-inflammatory drugs like 5-ASA by conjugating them with bile acids,¹¹ we're now discovering that they can enhance or inhibit cancer therapies, modify cardiovascular medications, and influence psychiatric drug responses. This isn't a niche finding. It's a paradigm shift that will require rethinking drug development, clinical trials, and personalized medicine.

The Bottom Line

The FMT-LUMINate trial and the research that preceded it have revealed a profound truth: your gut bacteria are active participants in cancer immunotherapy, not passive bystanders.

The most important insight isn't just that FMT works—it's how it works. By eliminating bacterial species that create a metabolically hostile environment and allowing beneficial species to produce immune-enhancing metabolites, FMT shifts the entire ecosystem toward immunological competence.

For patients facing cancer, this research offers both hope and actionable guidance. While FMT may not yet be accessible to most, the principles underlying its efficacy—protecting microbial diversity, avoiding antibiotics, supporting metabolite production through diet and lifestyle—are available now.

For clinicians, this represents an urgent call to integrate microbiome considerations into oncology practice. Screening for antibiotic use, educating patients about gut health, and exploring adjunctive interventions may directly impact treatment outcomes.

And for researchers, the path forward is clear: measure the metabolites directly, identify the super donors, engineer the optimal consortia, and bring precision microbiome medicine to the patients who need it most.

Stay curious. Take care of your microbes.

References

1. Duttagupta S, Messaoudene M, Hunter S, et al. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nat Med. 2026. [Epub ahead of print]
2. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-97.
3. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103.
4. Mager LF, Burkhard R, Pett N, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 2020;369(6510):1481-1489.
5. Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602-609.
6. Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595-602.
7. Hadi DK, Baines KJ, Jabbarizadeh B, et al. Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial. J Immunother Cancer. 2025;13:e012659.
8. Shi Z, Jiang W, Li H, et al. Faecalibacterium prausnitzii promotes anti-PD-L1 efficacy in natural killer/T-cell lymphoma by enhancing antitumor immunity. BMC Med. 2025;23(1):387.
9. Phelps CM, Willis NB, Duan T, et al. Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell. 2025;188:1-21.
10. Rueda GH, Causada-Calo N, Borojevic R, et al. Oral tryptophan activates duodenal aryl hydrocarbon receptor in healthy subjects: a crossover randomized controlled trial. Am J Physiol Gastrointest Liver Physiol. 2024;326:G687–G696.
11. Charron-Lamoureux V, Kelly P, Zuffa S, et al. Pan-repository analysis reveals a drug-activating function of microbial bile acid conjugation. Unpublished/Preprint. 2026.

This post accompanies the Lit Review Friday episode of Learn Something with Thaena.